Overview
WORK Medical Technology Group (Nasdaq: WOK), a Chinese medical device supplier, has entered into a strategic cooperation agreement with Shanghai Novabioplus Biotechnology Co., a provider of biological reagent products and solutions. The agreement, signed on April 13, 2026, aims to develop a "Data-Model-Application" trinity of next-generation intelligent medical models. The partnership is the latest advancement in WORK Medical's "Healthcare + Web3 + AI" strategy, specifically targeting biopharmaceutical R&D.
What the partnership involves
The collaboration integrates WORK Medical's AI algorithms with Novabioplus' protein datasets and multi-dimensional biological reagent platforms. The stated goal is to propel R&D of AI-driven protein antibody therapeutics.
Four specific "AI+" projects are planned:
- AI-based membrane protein design
- AI-driven antibody sequence optimization
- AI-enabled enzyme molecule design
- AI-powered peptide design
These projects combine data governance with model training to enable precise biomolecular design and functional simulation.
The BioToken model
A central element of the agreement is the intention to generate "BioTokens" — digital tokens representing biological data assets. The technical roadmap involves building an intelligent digital protein database that integrates protein sequences, functional data, and laboratory datasets. The parties aim to co-develop AI models for protein molecular design that can optimize protein structures and enhance biological functions while generating these tokens.
WORK Medical frames this as analogous to its exploration of medical real-world assets (RWA). The company states that BioTokens would transform biopharmaceutical R&D outputs into "verifiable and measurable digital assets."
Strategic context
WORK Medical describes the partnership as part of its evolution from a medical device manufacturer into a "life sciences digital ecosystem builder." The company's management stated that the initiative aims to "transcend the limitations of traditional asset-heavy RWA frameworks and explore new models for the assetization of life sciences data."
Novabioplus, founded by overseas-returned experts and senior scientists, holds invention patents in viral vector packaging, protein expression, functional cell lines, protein detection, and process impurity analysis. Its product portfolio includes transient protein expression kits, activity assay kits, quality research reagents, and recombinant protein products.
Tradeoffs and open questions
The press release does not specify a timeline for the four AI+ projects, nor does it detail how the BioToken model would be technically implemented or regulated. The tokenization of biological data raises questions about data provenance, consent, and valuation — none of which are addressed in the announcement. WORK Medical's current product portfolio consists of 23 medical device products, including masks and medical consumables, making the leap to AI-driven protein design a significant strategic pivot.
Bottom line
WORK Medical and Novabioplus have announced a plan to apply AI to protein design and tokenize the resulting biological data. The partnership is in its early stages, with no published technical specifications or commercial deployments. Readers should watch for concrete deliverables — trained models, published datasets, or regulatory filings — before assessing the viability of the BioToken model.